Disease-Modifying Agents Market, By Drug Class (Conventional Synthetic Disease-Modifying Agents, Biologic Disease-Modifying Agents, Targeted Synthetic Agents, Interferons, Monoclonal Antibodies, Immunomodulators and Others), By Indication, By Therapy Type, By Route of Administration, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV5942
|
Published Date
September 2026
|
Pages
288
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Disease-Modifying Agents Market size was valued at US$ 6,105.1 Million in 2025, expanding at a CAGR of 6.6% from 2026 to 2033.
Disease-modifying agents are a class of prescription drugs that modify the underlying disease mechanisms, such as the autoimmune response or inflammatory process, and reduce their progression, as opposed to only treating the symptoms. The market offers a range of traditional disease-modifying agents (TDMAs), including methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, mycophenolate, interferon beta, and glatiramer acetate.
Disease areas comprise rheumatoid arthritis, multiple sclerosis, lupus, and other autoimmune diseases. According to the MS International Federation, as of 2025, there are approximately 2.9 million people worldwide living with multiple sclerosis (MS). The overall market is dominated by established generic drugs, but there is also a need for differentiated injectable therapies. Additionally, the choice of therapy depends on the severity of the condition, safety, the need for monitoring, and the sequence of treatment options; therefore, the relevance of each drug depends on its indication and mechanism of action.
Disease-Modifying Agents Market- Market Dynamics
Expanding Chronic Autoimmune Disease Treatment Pool
The overall expanding treated population within autoimmune/inflammatory diseases contributes to the addressable base for existing disease-modifying therapies. In particular, according to the 2025 CDC analysis, there are 67.1 million U.S. adults with diagnosed arthritis, including 10.6 million individuals with rheumatoid arthritis. The Multiple Sclerosis International Federation reported that 2.9 million people worldwide are living with multiple sclerosis. As a result, disease prevalence boosts the therapies\' utilization as they usually address a chronic condition, which involves long-term treatment courses. Consequently, the continuous need for treatment affects the rate of initiation, monitoring, switches, and adherence. Thus, the presence of diseases contributes to the continuous utilization of drugs. Additionally, the class preference is dependent on the established treatment regimen, safety, convenience of administration, and disease control.
Disease-Modifying Agents Market- Segmentation Analysis:
The Global Disease-Modifying Agents Market is segmented on the basis of Drug Class, Indication, Therapy Type, Route of Administration, Distribution Channel, and Region.
By drug class, Conventional synthetic disease modifying agents (DMARDs) have a large proportion of total revenues due to the well-established and long term usage of methotrexate, leflunomide, hydroxychloroquine and sulfasalazine; especially in rheumatoid and other inflammatory diseases. Methotrexate remains the first line of choice DMARD for many patients who have moderate to severe levels of rheumatoid arthritis. Biologic and targeted synthetic agents are rapidly developing categories of DMARDs. This is primarily being driven by the ability to target TNF/JAK pathways which results in better control of disease and increased acceptance of these agents as second-line treatments when conventional therapies fail to provide an adequate response. It has been estimated by the World Health Organization (WHO) that there are approximately 18 million individuals living with rheumatoid arthritis across the globe.
Disease-Modifying Agents Market- Geographical Insights
North America remains an important strategic location due to specialist infrastructure development, established mechanisms for reimbursements, and the prevalence of autoimmune diseases enabling sustained use of disease-modifying products. According to CDC estimates for 2025, there are 67.1 million adult patients in the United States with diagnosed arthritis, 10.6 million of whom suffer from rheumatoid arthritis. Thus, there is a sufficiently large target patient population for conventional DMARDs. The addition of multiple sclerosis provides another specialized indication requiring prolonged treatment and monitoring. Moreover, regulatory activity impacts product access and substitution: the FDA has approved generic versions of siponimod and cladribine in 2025 for the treatment of multiple sclerosis. Thus, North America has sufficient clinical need combined with a well-established regulatory environment that incentivizes evidence-based, convenient treatment options.
Europe presents a significant market due to the established systems of rheumatology and neurology care, structured medical product assessments, and sustained management of chronic immune-mediated diseases. According to the UK MS Society, there are more than 150,000 people living with multiple sclerosis in the country and more than 7,100 new cases diagnosed each year demonstrating the consistent need for neurological treatments. The regulatory activity also shows continuous product turnover, in 2025, the EMA approved marketing authorization for Riulvy a generic tegomil fumarate intended for treating relapsing remitting multiple sclerosis. Approvals like these may expand product choice while increasing the pressure on the substitution of existing products. Conventional DMARDs remain integrated into guideline-based rheumatology practice-methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide.
Disease-Modifying Agents Market- Competitive Landscape:
Competition is distributed among diversified pharmaceutical companies, specialty immunology developers, and manufacturers supplying established or generic disease-modifying therapies. Differentiation increasingly depends on mechanism, administration frequency, safety profile, clinical evidence, and lifecycle expansion rather than product novelty alone. Novartis illustrates this transition through Kesimpta, its B-cell-directed therapy for relapsing multiple sclerosis. In September 2025, company reported ARTIOS and ALITHIOS findings indicated that more than 90% of relevant participants achieved no evidence of disease activity or remained progression-free under specified treatment settings. Biogen simultaneously maintained an established MS portfolio including Avonex and Plegridy, preserving the relevance of interferon-based therapies. Overall, competitive strength increasingly rests on evidence depth, convenience, and differentiated clinical positioning.
Recent Developments:
- In September 2025, Novartis announced new data regarding ARTIOS and ALITHIOS studies on Kesimpta in relapsing multiple sclerosis. Over 90% of patients reached particular disease control objectives, reinforcing the rationale for the use of the drug both initially and after switching.
- In July 2025, the European Medicines Agency (EMA)/Neuraxpharm granted marketing authorization to Riulvy, a generic tegomil fumarate, for relapsing-remitting multiple sclerosis. This approval increases the list of European products available for MS treatments.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL DISEASE-MODIFYING AGENTS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Biogen Inc.
- Merck KGaA
- Sanofi
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Eli Lilly and Company
- Bristol Myers Squibb
- UCB S.A.
- Bayer AG
- Viatris Inc.
- Fresenius Kabi
- Accord Healthcare
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Conventional Synthetic Disease-Modifying Agents
- Biologic Disease-Modifying Agents
- Targeted Synthetic Agents
- Interferons
- Monoclonal Antibodies
- Immunomodulators
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033
- Multiple Sclerosis
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis / Axial Spondyloarthritis
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2020 - 2033
- Combination therapy
- Monotherapy
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Oral
- Subcutaneous
- Intramuscular
- Intravenous / Infusion
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENTS
1. Disease-Modifying Agents Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Disease-Modifying Agents Market Snippet by Drug Class
2.1.2. Disease-Modifying Agents Market Snippet by Indication
2.1.3. Disease-Modifying Agents Market Snippet by Therapy Type
2.1.4. Disease-Modifying Agents Market Snippet by Route of Administration
2.1.5. Disease-Modifying Agents Market Snippet by Distribution Channel
2.1.6. Disease-Modifying Agents Market Snippet by Country
2.1.7. Disease-Modifying Agents Market Snippet by Region
2.2. Competitive Insights
3. Disease-Modifying Agents Key Market Trends
3.1. Disease-Modifying Agents Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Disease-Modifying Agents Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Disease-Modifying Agents Market Opportunities
3.4. Disease-Modifying Agents Market Future Trends
4. Disease-Modifying Agents Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Disease-Modifying Agents Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Disease-Modifying Agents Market Landscape
6.1. Disease-Modifying Agents Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Disease-Modifying Agents Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
7.1.2. Conventional Synthetic Disease-Modifying Agents
7.1.3. Biologic Disease-Modifying Agents
7.1.4. Targeted Synthetic Agents
7.1.5. Interferons
7.1.6. Monoclonal Antibodies
7.1.7. Immunomodulators
7.1.8. Others
8. Disease-Modifying Agents Market – By Indication
8.1. Overview
8.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
8.1.2. Multiple Sclerosis
8.1.3. Rheumatoid Arthritis
8.1.4. Psoriatic Arthritis
8.1.5. Ankylosing Spondylitis / Axial Spondyloarthritis
8.1.6. Systemic Lupus Erythematosus
8.1.7. Systemic Sclerosis
8.1.8. Others
9. Disease-Modifying Agents Market – By Therapy Type
9.1. Overview
9.1.1. Segment Share Analysis, By Therapy Type, 2025 & 2033 (%)
9.1.2. Combination therapy
9.1.3. Monotherapy
9.1.4. Others
10. Disease-Modifying Agents Market – By Route of Administration
10.1. Overview
10.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
10.1.2. Oral
10.1.3. Subcutaneous
10.1.4. Intramuscular
10.1.5. Intravenous / Infusion
10.1.6. Others
11. Disease-Modifying Agents Market – By Distribution Channel
11.1. Overview
11.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
11.1.2. Online Pharmacies
11.1.3. Hospital Pharmacies
11.1.4. Retail Pharmacies
11.1.5. Others
12. Disease-Modifying Agents Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
12.2. North America
12.2.1. Overview
12.2.2. Disease-Modifying Agents Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.2.5. North America Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.2.6. North America Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.2.7. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.2.8. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Disease-Modifying Agents Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.11.7. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.18. Denmark
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.18.3. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.18.4. Denmark Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.18.5. Denmark Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.18.6. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.18.7. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.19. Rest of Europe
12.3.19.1. Overview
12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.19.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.19.4. Rest of the Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.19.5. Rest of the Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.3.19.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3.19.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Disease-Modifying Agents Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.8. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.9.7. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.10.7. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.17. Taiwan
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.17.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.17.4. Taiwan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.17.5. Taiwan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.17.6. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.17.7. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.18. Vietnam
12.4.18.1. Overview
12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.18.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.18.4. Vietnam Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.18.5. Vietnam Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.18.6. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.18.7. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.19. Rest of APAC
12.4.19.1. Overview
12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.19.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.19.4. Rest of APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.19.5. Rest of APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.4.19.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4.19.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Disease-Modifying Agents Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.8. LATAM Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Disease-Modifying Agents Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.15. Iran
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.15.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.15.4. Iran Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.15.5. Iran Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.6.15.6. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.15.7. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.16. Qatar
12.6.16.1. Overview
12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.16.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.16.4. Qatar Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.16.5. Qatar Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.6.16.6. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.16.7. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.17. Rest of MEA
12.6.17.1. Overview
12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.17.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.17.4. Rest of MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.17.5. Rest of MEA Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
12.6.17.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6.17.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
13. Key Vendor Analysis- Disease-Modifying Agents Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. Biogen Inc.
13.2.2. Merck KGaA
13.2.3. Sanofi
13.2.4. Pfizer Inc.
13.2.5. Teva Pharmaceutical Industries Ltd.
13.2.6. Novartis AG
13.2.7. F. Hoffmann-La Roche Ltd.
13.2.8. AbbVie Inc.
13.2.9. Johnson & Johnson
13.2.10. Amgen Inc.
13.2.11. Eli Lilly and Company
13.2.12. Bristol Myers Squibb
13.2.13. UCB S.A.
13.2.14. Bayer AG
13.2.15. Viatris Inc.
13.2.16. Fresenius Kabi
13.2.17. Accord Healthcare
13.2.18. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL DISEASE-MODIFYING AGENTS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Biogen Inc.
- Merck KGaA
- Sanofi
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Eli Lilly and Company
- Bristol Myers Squibb
- UCB S.A.
- Bayer AG
- Viatris Inc.
- Fresenius Kabi
- Accord Healthcare
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Conventional Synthetic Disease-Modifying Agents
- Biologic Disease-Modifying Agents
- Targeted Synthetic Agents
- Interferons
- Monoclonal Antibodies
- Immunomodulators
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033
- Multiple Sclerosis
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis / Axial Spondyloarthritis
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2020 - 2033
- Combination therapy
- Monotherapy
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Oral
- Subcutaneous
- Intramuscular
- Intravenous / Infusion
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
- Others
GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
